8-K: Centessa Pharma Announces Positive Phase 1 Data for Orexin Agonist ORX750, Plans Phase 2 Trials

Centessa Pharmaceuticals reported positive interim Phase 1 clinical data for its orexin agonist, ORX750, showing significant improvements in wakefulness and a favorable safety profile, leading to plans for Phase 2 trials.

Summary

• Centessa Pharmaceuticals announced positive interim results from a Phase 1 trial of ORX750, a novel orexin receptor 2 agonist.
• The study involved acutely sleep-deprived healthy volunteers and showed that ORX750 significantly increased wakefulness compared to a placebo.
• The 2.5 mg dose of ORX750 restored normative wakefulness, with a mean sleep latency of 32 minutes on the Maintenance of Wakefulness Test (MWT), compared to 17 minutes for the placebo group.
• The 1.0 mg dose also showed a statistically significant increase in sleep latency, with a mean of 18 minutes compared to 10 minutes for the placebo group.
• ORX750 demonstrated a favorable safety and tolerability profile, with no serious adverse events and only mild, transient treatment-related adverse events.
• There were no observations of frequently reported on-target adverse events associated with other OX2R agonists, such as urinary issues, insomnia, or blood pressure increases.
• The pharmacokinetic profile of ORX750 supports a once-daily oral dosing regimen, with rapid absorption and dose-proportional systemic exposure.
• Acutely sleep-deprived volunteers receiving the 2.5 mg dose showed a significant 1.6 point improvement versus placebo in mean KSS score compared to baseline.
• The company plans to rapidly initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia starting in the fourth quarter of 2024.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results, a strong safety profile, and a clear path forward with Phase 2 trials. The management commentary is also very positive, indicating high confidence in the drug's potential. The only minor negative is the mention of mild adverse events, but these are not significant enough to lower the overall positive sentiment.

Positives

• ORX750 showed significant improvements in wakefulness in sleep-deprived individuals.
• The drug demonstrated a favorable safety and tolerability profile with no serious adverse events.
• The pharmacokinetic profile supports a convenient once-daily oral dosing.
• The 2.5 mg dose restored normative wakefulness, indicating strong efficacy.
• The company is rapidly advancing the drug into Phase 2 trials.

Negatives

• All observed treatment related adverse events were mild and transient, but they were still present.

Risks

• The success of Phase 2 trials is not guaranteed, and results may differ from Phase 1.
• Regulatory approvals are not guaranteed, and the timeline for approval is uncertain.
• The company faces competition from other companies developing treatments for sleep disorders.
• The company's ability to fund further development is dependent on future financing.

Future Outlook

The company plans to rapidly advance ORX750 into Phase 2 studies in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia beginning in the fourth quarter of 2024. They also plan to present preclinical data for ORX142 at Sleep Europe 2024.

Management Comments

• Saurabh Saha, MD PhD, Chief Executive Officer of Centessa, stated that the early data exceeded expectations, giving them the confidence to accelerate the program into the next stage of clinical development earlier than anticipated.
• Mario Alberto-Accardi PhD, President, Centessa Orexin Program, believes the data validates their unique structural biology driven orexin research platform and accelerates translation of their growing pipeline of orexin agonists.

Industry Context

This announcement is significant as it highlights the potential of orexin agonists in treating sleep-wake disorders, a market with substantial unmet needs. The positive results for ORX750 could position Centessa as a key player in this space, competing with other companies developing similar treatments.

Comparison to Industry Standards

• The mean sleep latency of 32 minutes achieved with the 2.5 mg dose of ORX750 is a strong result compared to existing treatments for sleep disorders, which often have lower efficacy or significant side effects.
• The favorable safety profile of ORX750, with no observations of frequently reported on-target adverse events associated with other OX2R agonists, is a key differentiator.
• Other companies such as Takeda and Idorsia are also developing orexin agonists, but Centessa's ORX750 appears to have a competitive profile based on the reported data.
• The rapid absorption and linear PK profile of ORX750, supporting once-daily oral dosing, is also a positive attribute compared to some other treatments that may require more frequent administration.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data and the advancement of ORX750 to Phase 2 trials.
• Patients with narcolepsy and idiopathic hypersomnia may benefit from this new treatment option if it proves successful in later trials.
• Employees of Centessa may be motivated by the positive results and the company's progress.
• The company's suppliers and partners may see increased business opportunities as the program advances.

Next Steps

• The company plans to rapidly initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia beginning in the fourth quarter of 2024.
• Preclinical data for ORX142 will be presented at Sleep Europe 2024.

Key Dates

Keywords

ORX750, Orexin Agonist, Sleep-Wake Disorders, Narcolepsy, Idiopathic Hypersomnia, Phase 1 Clinical Trial, Wakefulness, Maintenance of Wakefulness Test, MWT, KSS, Clinical Data, Pharmaceuticals